"We are thrilled to announce a significant leadership transition at Offspring Biosciences, marking an exciting new chapter for our company. Effective January 1st, 2025, Åsa Johansson will be stepping into the role of Chief Executive Officer (CEO), succeeding Anders Dahlstrand in this position.”
This change in leadership comes as Anders Dahlstrand, our former CEO, refocuses his role to leverage his deep expertise in business and science development. This strategic shift allows him to concentrate on areas where his extensive knowledge of the Pharmaceutical and CRO industries can best drive and develop Offspring's business. Anders will also continue to work as project leader in select projects for key customers, ensuring a continued connection to the core of Offspring’s research projects.
Åsa brings a wealth of experience to this role, with over ten years in leading positions across public and private sectors. Her career spans senior management roles in large operations units in the public sector, complemented by strategic leadership in the private sector and deep expertise in advanced analytics. This background makes Åsa perfectly positioned to lead our next growth phase.
As Head of Operations, Åsa has been instrumental in driving the success of our company, overseeing Operations, HR, and Finance. Her proven leadership, strategic vision, and energetic drive will be invaluable as we continue to innovate and advance our mission.
We are confident that this leadership transition will strengthen our company and position us for even greater success in the coming years. We look forward to a seamless transition and are excited about what the future holds for Offspring Biosciences under Åsa's leadership and Anders’ continued contributions.
We wish Åsa all the best in her new role, thank Anders for his dedicated leadership, and look forward to continuing to work with both Åsa and Anders at Offspring Biosciences.
//Anders Nordström, Chairman of the Board
"Åsa's operational excellence, analytical mindset and energetic drive will be instrumental in creating stronger value for our pharmaceutical partners and ultimately, patients." - Anders Dahlstrand
"I am thrilled and excited to succeed Anders Dahlstrand as the new CEO of Offspring.
Offspring is at an incredibly exciting stage, and I see numerous opportunities ahead. With our unique service offering, a team of highly competent and driven individuals, and a genuine ambition to truly make a difference for our customers, we are poised for a bright future. I hope to contribute with my leadership experience, new perspectives and a bit of competitive spirit as we strive to achieve our ambitious goals.
I want to express my sincere gratitude to Offspring's board for their trust in me to lead Offspring to the next level.” – Åsa Johansson, Chief Executive Officer
About Offspring Biosciences:
Offspring Biosciences, established in 2012 in Södertälje, Sweden, is a specialized contract research organization (CRO) providing preclinical biomarker assay solutions and molecular pathology services to pharmaceutical companies. The company has established itself through advanced histopathology-based analytics and recently strengthened its position through a strategic partnership with Flagship Biosciences, offering comprehensive biomarker solutions to support the drug development process, from early preclinical stages through Phase I-III clinical trials.